New drug cocktail aims to shrink head and neck melanoma before surgery
NCT ID NCT07353073
First seen Jan 21, 2026 · Last updated May 19, 2026 · Updated 20 times
Summary
This study tests a combination of three drugs (pucotenlimab, lenvatinib, and temozolomide) given before and after surgery for people with a rare type of skin cancer called head and neck mucosal melanoma. The goal is to see if this approach can shrink tumors and improve outcomes. About 30 adults aged 18 to 75 with resectable tumors will participate.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD AND NECK MUCOSAL MELANOMAS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shanghai Ninth People's Hospital affiliated to Shanghai Jiao Tong University School of Medicine
Shanghai, Shanghai Municipality, 200011, China
Conditions
Explore the condition pages connected to this study.